Table 1.
Summary of characteristics and results from randomized controlled trials included in this review
| Study | Year published | Country | Study design | Total number of patients (treatment, placebo) | Type of SIT | Type of allergens | Total duration (months) | Improvement | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Kaufman and Roth | 1974 | US | qRCT DB PC | 52 (26, 26) | SCIT | dander, HDM molds, pollen | 24 | (+) by physician | 27 |
| Warner et al. | 1978 | England | RCT DB PC | 20 (9, 11) | SCIT | HDM | 12 | (+) by patients | 28 |
| Glover and Atherton | 1992 | England | RCT DB PC | 24 (13, 11) | SCIT | HDM | 8 | (+) by patients | 29 |
| Silny and Czarnecka-Operacz | 2006 | Poland | RCT DB PC | 20 (10, 10) | SCIT | dander, HDM pollen | 12 | (+) by physician | 30 |
| Pajno et al. | 2007 | Italy | RCT DB PC | 56 (28, 28) | SLIT | HDM | 18 | (+) by physician | 31 |
| Novak et al. | 2012 | Germany | RCT DB PC | 168 (112, 56) | SCIT | HDM | 18 | (+) by physician | 32 |
| Qin et al. | 2013 | China | RCT DB PC | 107 (58, 49) | SLIT | HDM | 12 | (+) by physician | 33 |
SIT, specific immunotherapy; qRCT, quasi-randomized controlled trial; DB PC, double-blind placebo-controlled; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; HDM, house-dust mite; (+), Presence.